DUBLIN, January 10, 2022 / PRNewswire / –
- The campaign features real patients with Dupuytren’s contracture (DC) and aims to combat patient complacency, correct myths and misinformation, and highlight the tabletop test.
- Dupuytren’s contracture is a progressive condition of the hand that affects approximately 14 million Americans
Endo International plc (NASDAQ: ENDP) today announced the launch of its most recent TV advertising and disease awareness campaign, Watch education unfold. The campaign educates people about Dupuytren’s contracture (DC), a progressive hand disease that affects approximately 14 million Americans.
“We use the voices and experiences of real patients to share information about Dupuytren’s contracture and empower self-advocates,” said Thomas kolaras, Senior Vice President and General Manager, Medical Therapeutics at Endo. “This authenticity resonates with people – they can see themselves in the countryside and can consider speaking to a specialist at the hand about their options.”
“My patients with Dupuytren’s contracture tend to cope with the disease longer than necessary due to the conflicting information available,” said Dr. Heidi coryell shors, specialist in orthopedics and hand surgery. “In my opinion, Endo’s advertising and campaign could help many people who need the disease needlessly.”
Evolving Elway every day
Watch education unfold follows on from Endo’s previous awareness campaign, which featured a DC patient John elway. After gaining public attention with the help of the football legend, Endo focuses on the common people who have DC.
The new campaign sheds light on people’s hesitations and aims to correct misconceptions that can prevent many people from seeking treatment. It also highlights the simple tabletop test, which people can do right at home to determine if they need to see a hand specialist.
Watch education unfold encourages people who suspect they have CD or those who have been diagnosed with CD but have not been treated to speak to a hand specialist.
The 30 and 15 second commercials will air nationwide on television (including networks like ESPN and United States and during programs such as “Good Morning America” and “CBS Evening News”), streaming services (including Hulu and Discovery +) and online.
The campaign also includes digital and research ads, social media accounts and ads on platforms where patients are active, a digital partnership with Conde Nast, content on health-focused websites (including WebMD and Everyday Health), and educational materials in physician offices.
About Dupuytren’s contracture
DC is a lifelong condition that can get worse over time. It is caused by a buildup of collagen in the hand, which forms a cord-like cord that pulls the fingers towards the palm so that they cannot be straightened. As DC progresses, it can become difficult for individuals to use their hand (s) for daily tasks and activities.
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best lives through the provision of quality, life-enhancing therapies. Our decades of proven success come from passionate team members around the world who work together to deliver the best treatments. Together, we boldly transform knowledge into treatments that benefit those who need it, when they need it. Learn more about www.endo.com or contact us on LinkedIn.
Certain information contained in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities laws, including, but not limited to, statements. by M. Kolaras and Dr Shors. . Statements including words or expressions such as “believe”, “expect”, “anticipate”, “intend”, “estimate”, “plan”, “can”, “can”, “anticipate” “,” Intend “,” the future, “” potential “or similar expressions are forward-looking statements. All forward-looking statements contained in this press release reflect Endo’s current expectations regarding future events on the Company. based on trends and existing information and represent Endo’s judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting the business of Endo, including, but not limited to, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigation are or actual or contingent claims or liabilities, settlement discussions, negotiations or other adverse proceedings; our ability to satisfy judgments or settlements or pursue appeals, including bond requirements; our ability to adapt to changing market conditions; our ability to attract and retain key personnel; our inability to maintain financial covenants and operating obligations that would expose us to potential events of default on our outstanding debt; our ability to obtain additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or for general corporate or other purposes; our ability to refinance our debt; a significant reduction in our short- or long-term income that could prevent us from financing our operations and our liquidity needs or from repaying our debts. The occurrence or possibility of such an outcome has caused us to commit, and may result in further engagement in strategic reviews that may ultimately cause us to pursue one or more material business transactions or other corrective actions, including included as a preventive or proactive measure. These corrective actions could include a possible corporate reorganization, restructuring or bankruptcy involving all or part of our business, asset sales or other divestitures, cost reduction initiatives, corporate realignments. or strategic partnerships. Some of these measures may take a long time to implement and others may require the approval of a court or other third party. Such actions may be complex, could result in significant costs and charges or could otherwise have a negative impact on shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to them. us, or at all, or that they will result in the expected benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intention or obligation to update these forward-looking statements, except as required by law. Additional information regarding risk factors, including those referenced above, can be found in press releases issued by Endo, as well as in Endo’s public periodic filings with the United States Securities and Exchange Commission. and securities regulatory authorities in Canada, including the discussion under the heading “Risk Factors” in Endo’s most recent annual report on Form 10-K and any subsequent quarterly report on Form 10-Q or other documents filed with Securities and United States Exchange Commission.
SOURCE Endo International plc